Probiotic use in at-risk populations

Journal of the American Pharmacists Association

Volumn 56, Issue 6, 2016, Pages 680-686

  Sanders, Mary Ellen ^a   Merenstein, Daniel J ^a   Ouwehand, Arthur C ^a   Reid, Gregor ^a   Salminen, Seppo ^a   Cabana, Michael D ^a   Paraskevakos, George ^a   Leyer, Gregory ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROBIOTIC AGENT;

DIET SUPPLEMENTATION; DRUG APPROVAL; DRUG USE; GOOD MANUFACTURING PRACTICE; HEALTH CARE PERSONNEL; HEALTH CARE QUALITY; HUMAN; MEDICAL SPECIALIST; MICROBIAL CONTAMINATION; NOTE; PATIENT RISK; PHARMACIST; POPULATION RISK; PRODUCT SAFETY; UNITED STATES; DIETARY SUPPLEMENT; FOOD INDUSTRY; FOOD PACKAGING; ORGANIZATION AND MANAGEMENT; PROFESSIONAL STANDARD; QUALITY CONTROL; RISK FACTOR; STANDARDS;

DIETARY SUPPLEMENTS; FOOD INDUSTRY; FOOD LABELING; HUMANS; PHARMACISTS; PROBIOTICS; PROFESSIONAL ROLE; QUALITY CONTROL; RISK FACTORS; UNITED STATES;

EID: 84994462053     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1016/j.japh.2016.07.001     Document Type: Note

References (33)

1. 1 Hill, C., Guarner, F., Reid, G., et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 11:8 (2014), 506–514.
2. 2 Yi, S.H., Jernigan, J.A., McDonald, L.C., Prevalence of probiotic use among inpatients: a descriptive study of 145 U.S. hospitals. Am J Infect Control 44:5 (2016), 548–553.
3. 3 Vallabhaneni, S., Walker, T.A., Lockhart, S.R., et al. Notes from the field: fatal gastrointestinal mucormycosis in a premature infant associated with a contaminated dietary supplement–Connecticut, 2014. MMWR Morb Mortal Wkly Rep 64:06 (2015), 155–156.
4. 4 AlFaleh, K., Anabrees, J., Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev, 4, 2014, CD005496.
5. 5 Robinson, J., Cochrane in context: probiotics for prevention of necrotizing enterocolitis in preterm infants. Evid Based Child Health 9:3 (2014), 672–674.
6. 6 U.S. Food and Drug Administration. Generally Recognized as Safe (GRAS) Notification Program, 2014. Available at: http://www.fda.gov/animalveterinary/products/animalfoodfeeds/generallyrecognizedassafegrasnotifications/default.htm. Accessed August 9, 2016.
7. 7 Mattia, A., Merker, R., Regulation of probiotic substances as ingredients in foods: premarket approval or “generally recognized as safe” notification. Clin Infect Dis 46 Suppl 2 (2008), S115–S118 discussion S144-151.
8. 8 U.S. Food and Drug Administration. New Dietary Ingredients Notification Process. 2016, Washington, DC: U.S. Food and Drug Administration Available at: http://www.fda.gov/Food/DietarySupplements/NewDietaryIngredientsNotificationProcess/ Accessed August 9, 2016.
9. 9 EFSA Panel on Biological Hazards. Statement on the update of the list of QPS-recommended biological agents intentionally added to food or feed as notified to EFSA. 2: Suitability of taxonomic units notified to EFSA until March 2015. EFSA Journal, 13(6), 2015, 4138.
10. 10 Bourdichon, F., Casaregola, S., Farrokh, C., et al. Food fermentations: microorganisms with technological beneficial use. Int J Food Microbiol 154:3 (2012), 87–97.
11. 11 EUR-Lex. Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the environment of genetically modified organisms and repealing Council Directive 90/220/EEC - Commission Declaration. 2001 Available at: http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32001L0018 Accessed August 9, 2016.
12. 12 EUR-Lex. Regulation (EU) 2015/2283 of the European Parliament and of the Council of 25 November 2015 on novel foods, amending Regulation (EU) No 1169/2011 of the European Parliament and of the Council and repealing Regulation (EC) No 258/97 of the European Parliament and of the Council and Commission Regulation (EC) No 1852/2001 (Text with EEA relevance). 2015 Available at: http://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1449760581954&uri=OJ:JOL_2015_327_R_0001 Accessed August 9, 2016.
13. 13 Health Canada. Natural and Non-prescription Health Products Directorate. 2014 Available at: http://www.hc-sc.gc.ca/ahc-asc/branch-dirgen/hpfb-dgpsa/nhpd-dpsn/index-eng.php Accessed August 9, 2016.
14. 14 United States Pharmacopeial Convention. 2016. Available at: http://www.usp.org/. Accessed August 9, 2016.
15. 15 Boyle, R.J., Robins-Browne, R.M., Tang, M.L., Probiotic use in clinical practice: what are the risks?. Am J Clin Nutr 83:6 (2006), 1256–1264 quiz 1446-1447.
16. 16 Sanders, M.E., Akkermans, L.M., Haller, D., et al. Safety assessment of probiotics for human use. Gut Microbes 1:3 (2010), 164–185.
17. 17 van den Nieuwboer, M., Brummer, R.J., Guarner, F., et al. Safety of probiotics and synbiotics in children under 18 years of age. Benef Microbes 6:5 (2015), 615–630.
18. 18 van den Nieuwboer, M., Claassen, E., Morelli, L., et al. Probiotic and symbiotic safety in infants under two years of age. Benef Microbes 5:1 (2014), 45–60.
19. 19 Meini, S., Laureano, R., Fani, L., et al. Breakthrough Lactobacillus rhamnosus GG bacteremia associated with probiotic use in an adult patient with severe active ulcerative colitis: case report and review of the literature. Infection 43:6 (2015), 777–781.
20. 20 Goldstein, E.J., Citron, D.M., Claros, M.C., et al. Bacterial counts from five over-the-counter probiotics: are you getting what you paid for?. Anaerobe 25:Feb (2014), 1–4.
21. 21 Davis, C., Enumeration of probiotic strains: review of culture-dependent and alternative techniques to quantify viable bacteria. J Microbiol Methods 103:Aug (2014), 9–17.
22. 22 NSF International. 2016. Available at: http://www.nsf.org/. Accessed August 9, 2016.
23. 23 Food Chemical Codex, 2016, U.S. Pharmacopeial Convention, Rockville, MD.
24. 24 Natural Products Association. 2016.
25. 25 Carmody, R.N., Turnbaugh, P.J., Host-microbial interactions in the metabolism of therapeutic and diet-derived xenobiotics. J Clin Invest 124:10 (2014), 4173–4181.
26. 26 Geller, A.I., Shehab, N., Weidle, N.J., et al. Emergency department visits for adverse events related to dietary supplements. N Engl J Med 373:16 (2015), 1531–1540.
27. 27 Hempel, S., Newberry, S., Ruelaz, A., et al. Safety of probiotics used to reduce risk and prevent or treat disease. Evid Rep Technol Assess (Full Rep), 2011 Apr; (200), 1–645.
28. 28 Besselink, M.G., van Santvoort, H.C., Buskens, E., et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 371:9613 (2008), 651–659.
29. 29 Hemsworth, J.C., Hekmat, S., Reid, G., Micronutrient supplemented probiotic yogurt for HIV-infected adults taking HAART in London, Canada. Gut Microbes 3:5 (2012), 414–419.
30. 30 Villar-Garcia, J., Hernandez, J.J., Guerri-Fernandez, R., et al. Effect of probiotics (Saccharomyces boulardii) on microbial translocation and inflammation in HIV-treated patients: a double-blind, randomized, placebo-controlled trial. J Acquir Immune Defic Syndr 68:3 (2015), 256–263.
31. 31 Lee, J.Y., Chu, S.H., Jeon, J.Y., et al. Effects of 12 weeks of probiotic supplementation on quality of life in colorectal cancer survivors: a double-blind, randomized, placebo-controlled trial. Dig Liver Dis 46:12 (2014), 1126–1132.
32. 32 Offit PA, Erush S. Skip the supplements. The New York Times (New York), December 14, 2013. Available at: http://www.nytimes.com/2013/12/15/opinion/sunday/skip-the-supplements.html?_r=0. Accessed August 9, 2016.
33. 33 U.S. Food and Drug Administration. Dietary supplements–adverse event reporting. 2016, U.S. Food and Drug Administration, Washington, DC Available at: http://www.fda.gov/food/dietarysupplements/reportadverseevent/default.htm Accessed August 9, 2016.